BAB VI

DAFTAR PUSTAKA

1. Ahmad, F., Adil, M., Ullah, I., Ahmad, S., Hayat, Y., Ullah, H. M. 2015. Heart failure clinical outcomes in hyponatremic versus normonatremic patients. *J Postgrad Med Inst*. 29(2):72-5.
2. Ahmed, A., Aronow, W. S., Fleg, J. L. 2006. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. American Heart Journal. 151(2):444–450.
3. Ahmed, A., Aronow, W. S., Fleg, J. L. 2006. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. *American Heart Journal*. 151(2):444-450.
4. Akhter, M. W., Aronson, D., Bitar, F., Khan, S., Singh, H., Singh, R. P., Elkayam, U. 2004. Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. *The American Journal of Cardiology*. 94(7):957–960.
5. Albert, N. M., Nutter, B., Forney, J., Slifcak, E., Tang, W. H. W. 2013. A Randomized Controlled Pilot Study of Outcomes of Strict Allowance of Fluid Therapy in Hyponatremic Heart Failure (SALT-HF). *Journal of Cardiac Failure*. 19(1):1-9.
6. Avcı, B. K., Küçük, M., Müderrisoğlu, H., Eren, M., Kutlu, M. 2017. Relation between serum sodium levels and clinical outcomes in Turkish patients hospitalized for heart failure: a multi-center retrospective observational study. *www.anatoljcardiol.com*. 17:2-7
7. Azevedo, P. S., Polegato, B. F., Minicucci, M. F., Paiva, S. A. R., Zornoff, L. A. M. 2016. Cardiac Remodeling: Concepts, Clinical Impact, Pathophysiological Mechanisms and Pharmacologic Treatment. *Arquivos Brasileiros de Cardiologia*. 106(1):62-69.
8. Balling, L., Kistorp, C., Schou, M., Egstrup, M., Gustafsson, I., Goetze, J. P., Gustafsson, F. 2012. Plasma Copeptin Levels and Prediction of Outcome in Heart Failure Outpatients: Relation to Hyponatremia and Loop Diuretic Doses. *Journal of Cardiac Failure*. 18(5):351-358.
9. Barreras, A. P., Turner, C. K. 2003. Angiotensin II Receptor Blockers. *Bumc Proceedings*. 16:123-126.

10. Bhuvaneshwari, S., Saroj, P. V., Vijaya, D., Sowmya, M. S. Kumar, R. S. 2018. Hyponatremia Induced By Angiotensin Converting Enzyme Inhibitors And Angiotensin Receptor Blockers-A Pilot Study. *Journal Of Clinical And Diagnostic Research*. 12(7):FC01-FC03.
11. Braun, M. M., Barstow, C., Pyzocha, N. 2015. Diagnosis and Management of Sodium Disorders: Hyponatremia and Hypernatremia. *Ammerican Family Physician*. 91(5): 301-7.
12. Byung.-Su.,Choi, D.- Kang, S., Hwang, J., (2015). *Prognostic value of hyponatremia in heart failure patients: an analysis of the Clinical Characteristics and Outcomes in the Relation with Serum Sodium Level in Asian Patients Hospitalized for Heart Failure (COAST) study. The Korean Journal of Internal Medicine*, 30(4), 460.
13. Castagno, D., Jhund, P. S., McMurray, J. J. V., Lewsey, J. D., Erdmann, E., Zannad, F., Dargie, H. J. 2010. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. *European Journal of Heart Failure*. 12(6):607–616.
14. Cavalcante, P.A., Perilhão, M.S. da Silva, A., Serra, J. A., Júnior, F. A. Bocalini, D. S. 2015. Cardiac Remodeling and Physical Exercise: A Brief Review about Concepts and Adaptations. *International Journal of Sports Science*. 6(2): 52-61.
15. Coffey, S., Cox, B., Williams, M. J. 2016. Changing causes of heart valve disease mortality in New Zealand from 1988 to 2007. *www.nzma.org*. 129(1428): 55-62.
16. Corwin. E. 2000. Buku saku patofisiologi (*Handbook of pathophysiology*). Terjemahan Braham Pendit. Jakarta: EGC.
17. Cowie, M. R., Pearse, S. G. 2014. Heart failure: classification and pathophysiology. *Elsevier Ltd*.. 556- 561.
18. Dalimunthe, N. N., Harahap, S., Isnanta, R., Safri1, Z., Hasan, R. 2017. Hyponatremia on admission and its impact on clinical outcomes in patients hospitalized for heart failure. *Romanian Journal of Cardiology* .27(1): 29-32.
19. Damman, K., Testani, J. M. 2015. The kidney in heart failure: an update. European *Heart Journal*. 36(23):1437–1444.
20. Damman, K., Valente, M. A. E., Voors, A. A., O'Connor, C. M., van Veldhuisen, D. J., Hillege, H. L. 2013. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. *European Heart Journal*. 35(7):455–469.

21. Darmadi, 2013. Patofisiologi dan Tata Laksana Remodeling Kardiak. *Cermin Dunia Kedokteran*. 40(9):651- 654.
22. Elisaf, M., Theodorou, J., Pappas, C., Siamopoulos, K. 1995. Successful Treatment of Hyponatremia with Angiotensin-Converting Enzyme Inhibitors in Patients with Congestive Heart Failure. Department of Internal Medicine. *University of Ioannina, Greece.* 86:477-480.
23. Filippatos, T. D., Elisaf, M. S. 2013. Hyponatremia in patients with heart failure. *World Journal of Cardiology*. 5(9): 317-.328.
24. Flather, M. D., Gollop, N. D. 2016. Understanding Mechanisms of Action of Beta-Blockers in Heart Failure With Reduced and Preserved Ejection Fraction. *The American College Of Cardiology Foundation.* 4(2): 150-1.
25. Ganiger, H., Ravishankar, A. G. 2015. Dysnatraemia in Heart Failure: A Descriptive Study. *Int J Sci Stud.* 3(6):81-85.
26. Gerber, Y., Weston, S. A., Redfield, M. M., Chamberlain, A. M., Manemann, S. M., Jiang, R., … Roger, V. L. 2015. A Contemporary Appraisal of the Heart Failure Epidemic in Olmsted County, Minnesota, 2000 to 2010. *JAMA Internal Medicine*. 175(6):996.
27. Ghali, J. K., Tam, S. W. 2010. The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists. *J Card Fail*. 16: 419-431.
28. Gheorghiade, M. 2007. Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart FailureThe EVEREST Clinical Status Trials. *The Journal Of The American Medical Association*. 297(12):1332- 1343.
29. Greenberg, B. R. 1994. Congestive Heart Failure as a Consequence of Valvular Heart Disease. *Springer-Verlag New York, Inc*. 234-236.
30. Hamaguchi, S., Kinugawa, S., Tsuchihashi-Makaya, M., Matsushima, S., Sakakibara, M., Ishimori, N., Tsutsui, H. 2014. Hyponatremia is an independent predictor of adverse clinical outcomes in hospitalized patients due to worsening heart failure. *Journal of Cardiology*. 63(3):182-188.
31. Harnett, J. D., Foley, R. N., Kent, G. M., Barre, P. E., Murray, D. Parfrey, P. S. 1995. Congestive Heart Failure In Dialysis Patients: Prevalence, Incidence, Prognosis And Risk Factors. *Kidney International*. 47: 884-890.
32. Hauptman, P. J., Burnett, J., Gheorghiade, M., Grinfeld, L., Konstam, M. A., Kostic, D., Udelson, J. E. 2013. Clinical Course of Patients With Hyponatremia and Decompensated Systolic Heart Failure and the Effect

of Vasopressin Receptor Antagonism With Tolvaptan. *Journal of Cardiac Failure*. 19(6):390-97.

33. Higgins, C. 2016. Urea and the clinical value of measuring blood urea concentration. *acutecaretesting.org*. 1-5.
34. Hoorn, E. J., & Zietse, R. (2011). Hyponatremia and Mortality: How Innocent is the Bystander? Clinical Journal of the American Society of Nephrology, 6(5), 951–953.
35. Hwang, S. J., Melenovsky, V., Borlaug, B. A. 2014. Implications of Coronary Artery Disease in Heart Failure With Preserved Ejection Fraction. *Journal of the American College of Cardiology*. 63(25):2817-27.
36. Ishikawa, S. 2015. Hyponatremia Associated with Heart Failure: Pathological Role of Vasopressin-Dependent Impaired Water Excretion. *Journal of Clinical Medicine*. 4(5):933-947.
37. Iwano, H., Little, W. C. 2013. Heart failure: What does ejection fraction have to do with it? *Journal of Cardiology*. 62(1):1-3.
38. Johnson, D., Jin, Y., Quan, H., Cujec, B. 2003. Beta-blockers and angiotensin-converting enzyme inhibitors/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada. *Journal of the American College of Cardiology*. 42(8):1438-45.
39. Jones, N. R., Hobbs, R., Taylor, C. J. 2017. Prognosis following a diagnosis of heart failure and the role of primary care: a review of the literature. *BJGP Open*.1- 8.
40. Kajimoto, K., Sato, N., Takano, T. 2015. Relation between elevated blood urea nitrogen, clinical features or comorbidities, and clinical outcome in patients hospitalized for acute heart failure syndromes. *International Journal of Cardiology*. 201:311-314.
41. Kementrian Kesehatan RI. 2014. Pusat Data dan Informasi Kesehatan RI: Situasi Jantung Kita. 1-7.
42. Klein, L., Massie, B. M., Leimberger, J. D., O'Connor, C. M., Pina, I. L., Adams, K. F. 2008. Admission or Changes in Renal Function During Hospitalization for Worsening Heart Failure Predict Postdischarge Survival: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). *American Heart Ascociation Journal*.1(1):25–33.
43. Klein, L., Connor, C. M., Leimberger, J. D., Gattis-Stough, Pina, I. L., Felker, G. M., Adams, K. F., Califf, R. M., Gheorghiade, M. 2005. Lower serum

sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 111:2454-2460.

44. Klip, I. T., Postmus, D., Voors, A. A., Brouwers, F. P., Gansevoort, R. T., Bakker, S., *et al.* 2015. Hemoglobin levels and new-onset heart failure in the community. *Am Heart J* 169(1):94-101.
45. Konstam, M. A. 2007. Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart FailureThe EVEREST Outcome Trial. *The Journal Of The American Medical Association*. 297(12):1319-331
46. Kottgen, A., Russell, S. D., Loehr, L. R., Crainiceanu, C. M., Rosamond, W. D., Chang, P. P., Coresh, J. 2007. Reduced Kidney Function as a Risk Factor for Incident Heart Failure: The Atherosclerosis Risk in Communities (ARIC) Study. *Journal of the American Society of Nephrology*.18(4):1307–1315.
47. Lam, C., Gamble, G. D., Ling, L. H., Sim, D., Leong, K., Yeo, P., *et al*. 2018. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. *European Heart Journal*. 39(20): 1770-1780.
48. Licata, G., Pasquale, P., Parrinello, G., Cardinale, A., Scandurra, A., Follone, G., Argano, C., Tuttolomondo, A., Paterna, S. 2003. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. *Am Heart J*. 145: 459-466.
49. Lilly, L. S. 2016. Patophysiology Of Heart Disease : A Collaborative Project Of Medical Students And Faculty 6th Edition.
50. Lin, J. L., Hsu, H. Y. 2010. Study of Sodium Ion Selective Electrodes and Differential Structures with Anodized Indium Tin Oxide. *Sensors*.10(3):1798–1809.
51. Madden, N., & Trachtman, H. 2015. Physiology of the Developing Kidney: Sodium and Water Homeostasis and Its Disorders. *Pediatric Nephrology*. 181–217.
52. Magyar, K., Gal, R., Riba, A., Habon, T., Halmosi, R., Toth, K. 2015. From hypertension to heart failure. *World J Hypertens*. 5(2): 85-92.
53. Masarone, D., Limongelli, G., Rubino, M., Valente, F., Vastarella, R., Ammendola, E., Pacileo, G. 2017. Management of Arrhythmias in Heart Failure. *Journal of Cardiovascular Development and Disease*. 4(1):1-20.
54. Mansoor, A., Ather, A. A., Hameed, B., Khosa, M., Kahn, I. M., Khalid. R. 2017. Association of Mortality with Hyponatremia in patients of Heart

Failure. *Department of Medicine, KEMU/Mayo Hospital, Lahore*. 11(3):990-988.

55. Meluzín, J., & Tomandl, J. 2015. Can Biomarkers Help to Diagnose Early Heart Failure with Preserved Ejection Fraction? Disease Markers. *Hindawi Publishing Corporation*. 1-9.
56. Nankabirwa, H., Kalyesubula, R., Ssinabulya, I., Katabira, E. T., Cumming, R. G. 2016. A cross-sectional study of hyponatraemia among elderly patients with heart failure in Uganda. *BMJ Open*. 6(5):1-7.
57. Patel, S. S., Molnar, M. Z., Tayek, J. A., Ix, J. H., Noori, N., Benner, D., Kalantar-Zadeh, K. 2012. Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. *Journal of Cachexia, Sarcopenia and Muscle*. 4(1):19–29.
58. Paterna, S., Pasquale, P., Parrinello, G., Amato, P., Cardinale, A., Follone, G., Giubilato, A., Licata, G. 2000. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. *Eur J Heart Fail*. 2: 305-313.
59. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI). 2015. Pedoman Tatalaksana Gagal Jantung.
60. Perkumpulan Endokrinologi Indonesia. 2015. Konsensus Pengendalian dan Pencegahan Diabetes Mellitus Tipe 2 di Indonesia. PB. PERKENI.Jakarta.
61. Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S. Van Der Meer, P. 2016. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *European Heart Journal*. 37(27):2129–2200.
62. Purek, L. 2006. Coronary artery disease and outcome in acute congestive heart failure. *Heart Journal*. 92(5):598-602.
63. Rhee M., Ayus, J. C., Zadeh, K.K., 2019. Hyponatremia in the Dialysis PopulationConnie M. Rhee1, Juan Carlos Ayus1,2and Kamyar Kalantar-Zadeh1,3International Society of Nephrology.
64. Sahay, M., Sahay, R. 2014. Hyponatremia: A practical approach. *Indian Journal of Endocrinology and Metabolism*. 18(6):760-770.
65. Sands, J. M. 2003. Mammalian Urea Transporters. *Annual Review of Physiology*. 65(1): 543-566.
66. Sarma, S., Mentz, R. J., Kwasny, M. J., Fought, A. J., Huffman, M., Subacius, H., *et al.* 2013. Association between diabetes mellitus and post-discharge

outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. *Eur J Heart Fail* 15(2):194-202.

67. Siregar, P. 2016. Buku Ajar Ilmu Penyakit Dalam edisi 6 jilid II: Gangguan Air dan Elektrolit. Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI). 2241-45.
68. Soelistijo, S. A. 2015. Konsensus Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Di Indonesia 2015. PB. Perkeni.
69. Strait, J. B., Lakatta, E. G. 2012. Aging-Associated Cardiovascular Changes and Their Relationship to Heart Failure. Heart Failure Clinics. 8(1):143-164.
70. Taylor, C. J., Roalfe, A. K., Iles, R., Hobbs, F. D. R. 2012. Ten-year prognosis of heart failure in the community: follow-up data from the Echocardiographic Heart of England Screening (ECHOES) study. *European Journal of Heart Failure*. 14(2):176–184.
71. Vaartjes, I., Hoes, A., Reitsma, J., de Bruin, A., Grobbee, D., Mosterd, A., *et al*. 2010. Age-and gender-specific risk of death after first hospitalization for heart failure. *BMC Public Health*.10(1)
72. Van Deursen, V. M., Urso, R., Laroche, C., Damman, K., Dahlstrom, U., Tavazzi, L., *et al* . 2014. Co-morbidities in patients with heart failure: an analysis of the European heart failure pilot survey. *Eur J Heart Fail*. 16(1):103–111.
73. Van der Meer, P., Voors, A. A., Lipsic, E., Van Gilst, W. H., Van Veldhuisen, D. J. 2004. Erythropoietin in cardiovascular diseases. *Eur Heart J*. 25:285–291.
74. Van der Wal, H. H., Van Deursen, V. M., Van der Meer, P., Voors, A. A. 2017. Comorbidities in Heart Failure. *Handbook of Experimental Pharmacology*. 35–66.
75. Verbalis, J. G., Goldsmith, S. R., Greenberg, A., Korzelius, C., Schrier, R. W., Sterns, R. H., & Thompson, C. J. 2013. Diagnosis, Evaluation, and Treatment of Hyponatremia: Expert Panel Recommendations. *The American Journal of Medicine*. 126(10):S1–S42.
76. Velagaleti, R., Vasan, R. S., 2007. Heart Failure in the 21st Century: Is it a Coronary Artery Disease Problem or Hypertension Problem?. *NIH Public Access* . 25(4): 487–490.
77. Verbrugge, F. H., Steels, P., Grieten, L., Nijst, P., Tang, W., Mullens, W. 2015. Hyponatremia In Acute Decompensated Heart Failure. *Journal Of The American College Of Cardiology*. 6(5): 480 - 92.

78. Wang, T. J. 2003. Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality: The Framingham Heart Study. *American Heart Ascociation Journal*. 107(23):2920–25.
79. Wessly, P., Soherwardi, S., Gandotra, C. 2016. Hyponatremia in Congestive Failure: Evidence Based Management. *Austin Intern Med*. 1(1):1-5.
80. Westenbrink, B. D., Visser, F. W., Voors, A. A., Smilde, T. D., Lipsic, E., Navis, G., *et al* . 2007. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. *Eur Heart J* 28(2):166–171.
81. Wouter, O., Voors, A., Zwinderman, A. 2014. Factors Influencing the Predictive Power of Models for Predicting Mortality and or Heart-Failure Hospitalization in Patients With Heart Failure . *The American College Of Cardiology Foundation*. 1-8.
82. Yoo, B. S., Park, J. J., Choi, D. J., Kang, S. M., Hwang, J. J., Lin, S. J. 2015. Prognostic value of hyponatremia in heart failure patients: an analysis of the Clinical Characteristics and Outcomes in the Relation with Serum Sodium Level in Asian Patients Hospitalized for Heart Failure (COAST) study. *The Korean Journal of Internal Medicine*. 30(4):460-66.
83. Ziaeian, B., Fonarow, G. C. 2016. Epidemiology and aetiology of heart failure. *Nature Reviews Cardiology*. 13(6):368–378.